US Pharma and Biotech Summit
The US biopharmaceutical industry faces relentless disruption. America still leads the world in high-risk drug development, and revolutionary treatments may shape a new era of healthcare. But the path from innovation to access is beset by uncertainty around policy, regulation and investment.
Organized by FT Live in collaboration with Endpoints News, the event brought together top executives, investors and experts to share powerful insights into the future of life sciences in America and worldwide.
.jpg)
Speakers included
Key Themes
Artificial intelligence in life sciences
Where is AI delivering return on investment for biopharma companies?
.png)
Dealmaking environment
Is dealmaking activity set to surge with rate cuts?
Clinical trial agility
How are industry-wide shifts in R&D affecting pipeline success rates?
"I really enjoyed CEO insights. When you know what they are thinking we can design our strategies accordingly." - Vice President, Pfizer
Othe Summits and Free Webinars in the Series
Speaking Opportunities
Ben Graham
ben.graham@ft.com
Sponsorship
Rachel Joy
rachel.joy@ft.com
Delegate Services
Joshua Goddard
joshua.goddard@ft.com
Supporting Partners
Join our mailing list
Stay up to date with the latest news, events and offers from FT Live.
© Financial Times Live
FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice
